We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

000830:SZSELuxi Chemical Group Co., Ltd. Analysis

Data as of 2026-09-09 - not real-time

CN¥12.83

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Luxi Chemical Group Co., Ltd. trades at ¥12.83, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. RSI sits at 55.0, which reads as neutral, and MACD momentum is bullish. Watch ¥11.66 as support and ¥13.69 as the nearer resistance level.
Multiples put this in fair territory at a P/E of 22.1. Consensus targets land 60.6% above where the shares trade now. Revenue is growing at 10.6% on a 3.8% profit margin. The 1.55% dividend yield looks covered by current payout levels.
Risk scores 5 out of 10, which is moderate for this asset class. With 30-day volatility of 32.3%, a beta of -0.07 and a maximum drawdown of 44.1%, position sizing matters here. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 3/10.

Top Market Events

See Luxi Chemical Group Co., Ltd. 000830.SZ stock analyst estimates, including earnings and revenue, EPS, upgrades and...See Luxi Chemical Group Co., Ltd. 000830.SZ stock analyst estimates, including earnings and revenue, EPS, upgrades and...Get the latest Luxi Chemical Group Co., Ltd. 000830.SZ stock news and headlines to help you in your trading and...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 15.09
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 15.09
  • Analyst targets imply +60.6% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • Analyst targets imply +60.6% versus the current price
  • Revenue growth of +10.6%
  • P/E ratio of 22.1

Key Metrics & Analysis

Financial Health

Revenue Growth10.60%
Profit Margin3.76%
P/E Ratio22.1
ROE5.79%
ROA2.56%
Debt/Equity58.60
P/B Ratio1.2
Op. Cash FlowCN¥2.6B
Free Cash FlowCN¥326.8M

Technical Analysis

TrendBearish
RSI55.0
SupportCN¥11.66
ResistanceCN¥13.69
MA 20CN¥12.37
MA 50CN¥12.42
MA 200CN¥15.09
MACDBullish
VolumeIncreasing
Fear & Greed Index92.04

Valuation

Target PriceCN¥20.60
Upside/Downside60.56%
GradeFair
TypeBlend
Dividend Yield1.55%

Risk Assessment

Beta-0.07
Volatility32.33%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.